# BAYRY PDUFA Calendar: FDA Decision Dates & Catalyst Timeline

Canonical URL: https://biopharmsignal.com/pdufa-calendar/BAYRY
Company: Bayer AG

BioPharmSignal tracks active PDUFA and FDA decision milestones associated with BAYRY.

## BAYRY PDUFA Milestones

- 2026-11-30 — PDUFA — FDA granted accelerated approval to HYRNUO as first-line therapy. FDA granted accelerated approval to HYRNUO for adults with locally advanced or metastatic n...
  Company: Bayer AG
  Source: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small
  Event detail: https://biopharmsignal.com/pdufa-calendar/BAYRY/hyrnuo-first-line-her2-mutated-nsclc.md
  Month page: https://biopharmsignal.com/pdufa-calendar/2026/november (November 2026)

## Related Pages

- Company page: https://biopharmsignal.com/company/BAYRY
- Interactive PDUFA Calendar: https://biopharmsignal.com/pdufa-calendar

## FAQ

### What does the BAYRY PDUFA calendar show?

It shows active PDUFA and FDA decision milestones associated with BAYRY, including decision dates, application stage, and summary details when available.
### Where can I find more context for BAYRY?

Use the BioPharmSignal company page for BAYRY to read related news, stock data, sector context, and company-specific updates.
### Are these dates investment advice?

No. PDUFA dates are research inputs, not investment recommendations. Always review primary sources and understand the clinical and regulatory context.